Positive Phase III data for Radius Health's abaloparatide in postmenopausal osteoporosis

17 August 2016

The results of a Phase III trial of abaloparatide, from US pharma company Radius Health (Nasdaq: RDUS), suggest it significantly reduces fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo.

These positive results from the 2,463-patient, Phase III ACTIVE trial have been published in the Journal of the American Medical Association (JAMA), and showed fewer new vertebral and non-vertebral fractures in the abaloparatide arm after 18 months of treatment.

Paul Miller, medical director at the Colorado Center for bone research and lead author of the paper, said: “The landmark ACTIVE trial results are important and further validate abaloparatide’s potential to consistently, substantially and rapidly reduce both new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK